ChemLex
AI-for-science company running a 24/7 autonomous "self-driving" chemistry lab in Singapore that designs, synthesizes and analyzes molecules robotically.
1. Core Product / Service
ChemLex builds an AI + robotics platform for automated chemical synthesis: AI-driven retrosynthesis prediction feeds a fully automated synthesis line that designs, makes and analyzes molecules in a closed loop with real-time feedback [1]. The company reports the line runs 800+ reactions per day, replaces roughly 90% of manual operations, and improves throughput 2–4× over traditional synthesis [1][3].
Public reporting emphasizes the self-driving lab itself — with chemical building blocks as the unit of synthesis — as the core asset [3].
2. Target Users & Pain Points
- Pharma / biotech discovery teams that need compounds made and validated fast — reported 70+ customers worldwide, including 6 of the top 10 global pharma companies [1][2].
- Chemistry / materials teams outsourcing reaction optimization and high-throughput experimentation.
Pain solved: manual synthesis is the slow, labor-bound step between a design and a testable molecule. ChemLex turns "make this molecule" into an automated, API-like loop, compressing the design–make–test cycle that otherwise sits inside a CRO or an in-house bench.
3. Competitive Landscape
| Player | Type | Vs. ChemLex |
|---|---|---|
| Enamine | Compound / building-block library | Catalog scale, but manual/contract synthesis, less AI-native |
| Mcule | Online building-block marketplace | Procurement layer without a self-driving synthesis lab |
| xtalpi | AI drug discovery + automation | Full drug-discovery platform; ChemLex is synthesis-focused |
| adaptyv-bio | Automated protein-validation lab | Validation of proteins, not small-molecule synthesis |
ChemLex differentiates on the autonomous synthesis loop — the 24/7 robotic line is the moat, versus catalog or software-only competitors.
4. Unique Observations
- China → Singapore AI-for-science export. ChemLex is a Chinese-founded company that relocated to Singapore's One-North and is being showcased by the Singapore EDB as part of the city-state's life-sciences ecosystem [2][3]. It's a concrete instance of AI4S capability migrating to jurisdictions with strong pharma demand and a neutral IP position.
- Merck MOU as enterprise signal. The Jan 2026 Merck memorandum (automated chemistry, reaction optimization, high-throughput experimentation) is the kind of validation that matters more than the funding number — a top chemistry supplier betting on autonomous synthesis [4].
5. Financials / Funding
- Series A: reported ~US$26M (pre-Singapore-expansion) [1].
- Series A+: US$45M, announced Dec 8, 2025, led by Granite Asia, with Qiming Venture Partners, LYFE Capital and Sinovation Ventures [1][2]. Total raised ~US$80M.
- Revenue / customers: 70+ customers, 6 of the top 10 global pharma [1].
6. People & Relationships
- Founder / CEO: Dr. Sean Lin [2][3].
- Origin: founded 2022 in Shanghai; Singapore entity incorporated Feb 2024; lab at One-North, Ayer Rajah Crescent [2][3].
- Partners: EDDC (A*STAR's Experimental Drug Development Centre, first Singapore partner), Merck (MOU Jan 2026), member of the PIPS pharma-innovation consortium [2][4].
- Investors: Granite Asia, Qiming Venture Partners, LYFE Capital, Sinovation Ventures.
- Peers / adjacent: xtalpi, adaptyv-bio, Enamine, Mcule.